MwanzoADAP • NASDAQ
add
Adaptimmune Therapeutics PLC - ADR
$ 0.27
Baada ya Saa za Kazi:(3.84%)+0.010
$ 0.28
Imefungwa: 25 Apr, 18:21:31 GMT -4 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 0.27
Bei za siku
$ 0.26 - $ 0.28
Bei za mwaka
$ 0.20 - $ 1.48
Thamani ya kampuni katika soko
68.24M USD
Wastani wa hisa zilizouzwa
2.43M
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 3.22M | 1,294.81% |
Matumizi ya uendeshaji wa biashara | 28.56M | 199.64% |
Mapato halisi | -74.22M | -54.88% |
Kiwango cha faida halisi | elfu -2.30 | 88.90% |
Mapato kwa kila hisa | -0.24 | 0.25% |
EBITDA | -61.68M | -55.60% |
Asilimia ya kodi ya mapato | -2.33% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 151.60M | 3.18% |
Jumla ya mali | 245.96M | -12.97% |
Jumla ya dhima | 234.11M | -3.70% |
Jumla ya hisa | 11.85M | — |
hisa zilizosalia | 257.23M | — |
Uwiano wa bei na thamani | 5.33 | — |
Faida inayotokana na mali | -57.25% | — |
Faida inayotokana mtaji | -134.10% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -74.22M | -54.88% |
Pesa kutokana na shughuli | -34.20M | -133.06% |
Pesa kutokana na uwekezaji | 8.17M | -88.02% |
Pesa kutokana na ufadhili | elfu 1.00 | -98.65% |
Mabadiliko halisi ya pesa taslimu | -26.22M | -148.60% |
Mtiririko huru wa pesa | -14.80M | 45.36% |
Kuhusu
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park. In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2008
Tovuti
Wafanyakazi
506
